OBJECTIVE: To investigate the effects of low-dose risedronate sodium on the in vitro cellular profile of osteoblasts, adipocytes, osteocytes and osteoclasts in a rat model of abrupt oestrogen deficiency. METHODS: Oestrogen deficiency was induced by ovariectomy in 24 female rats. The rats were treated with low-dose (0.24 µg/kg) or high-dose (2.4 µg/kg) risedronate sodium for 4 days presurgery, continuing every 3 days until 15 days postsurgery. Osteogenic and adipogenic differentiation were determined in cultured bone marrow cells by alkaline phosphatase and Oil Red O staining, respectively, and by osteogenic and adipogenic gene expression. Osteoclast formation was measured in bone marrow cells stimulated with macrophage colony-stimulating factor and receptor activator of nuclear factor kB ligand, and stained with tartrate-resistant acid phosphatase. Osteocyte apoptosis was assessed by terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick-end labelling assay and B-cell lymphoma-2 (Bcl-2) immunohistochemistry.
Introduction
Osteoporosis is characterized by disruption of trabecular bone structure and loss of mineralized bone, which increase the risk of fracture. 1,2 Oestrogen deficiency is a critical factor that leads to bone loss in women because it plays an important role in the regulation of bone marrow mesenchymal stem cell differentiation into osteoblasts and adipocytes. 1,3 A reduction in the osteogenic potency and an increase in the adipogenic capacity of mesenchymal stem cells has been reported in patients with osteoporosis. 4 Oestrogen may, therefore, exert primary effects on the fate of mesenchymal stem cells that result in reduced bone formation and G Wang, Z Zhu, C Lei et al. Low-dose risedronate and bone protection enhanced fat formation in patients with osteoporosis.
Risedronate sodium is a bisphosphonate known to be effective in the treatment of postmenopausal osteoporosis, 5 -10 glucocorticoid-induced osteoporosis 11 and Paget's disease. 12 It is unknown if risedronate sodium is effective in reversing the primary effects of oestrogen deficiency on mesenchymal stem cell fate in vivo, or if risedronate has any effects on the fate of other bone-derived cells such as osteoclasts and osteocytes.
Although proven to be effective in preventing bone loss, the use of risedronate sodium requires long-term follow-up because bisphosphonates can accumulate in bone, causing adverse events such as osteonecrosis of the jaw. 13 -15 Long-term treatment with risedronate sodium also suppresses bone turnover, increases microdamage and reduces the mechanical properties of bone in canine ribs. 16 Reducing the dose of risedronate sodium dose may be beneficial in limiting the potential for long-term side-effects.
The present study aimed to investigate the effects of low-dose risedronate sodium on mesenchymal stem cells, osteoclasts and osteocytes in ovariectomized rats, and also to determine whether low-dose risedronate sodium had a protective effect on the bone cells examined.
Materials and methods

ANIMALS AND TREATMENT GROUPS
This study used 24 female Sprague-Dawley rats (Sino-British Sippr/BK Lab Animal Ltd, Shanghai, China) aged 6 months and mean ± SD weight 286.4 ± 15.3 g. The rats were housed together at 24 -26°C in a 12-h light-dark cycle and with food and water ad libitum. They were divided into to one of four treatment groups: (i) sham surgery; (ii) ovariectomy control; (iii) ovariectomy plus low-dose (0.24 µg/kg) risedronate sodium;
(iv) ovariectomy plus high-dose (2.4 µg/kg) risedronate sodium. Doses of risedronate sodium were chosen based on published data. 17 Risedronate sodium in 0.9% saline or 0.9% saline control (1 ml) were administered by intraperitoneal (i.p.) injection at 09:00 h every 3 days, from 4 days prior to ovariectomy until 15 days postsurgery. All experiments were carried out in a specific pathogen-free laboratory.
As described previously, 18 the rats underwent bilateral ovariectomy by lumbar incision under diethyl ether anaesthesia, 1 h after the second i.p. injection of risedronate sodium or saline control on day 4. The ovaries and surrounding adipose tissue on both sides of the abdomen were ligated and dissected. Rats were sacrificed for tissue harvesting on day 15 postsurgery 6 h after the last injection of risedronate sodium or saline control.
The Animal Care and Experiment Committee of Shanghai Jiao Tong University School of Medicine approved all experimental procedures, and the study was carried out according to the guidelines for Ethical Conduct in the Care and Use of Nonhuman Animals in Research by the American Psychological Association.
CELL PROLIFERATION ASSAY
Bone marrow stromal cells (BMSCs) were cultured from ovariectomized rat bone marrow cells, as described previously. 19 Briefly, BMSCs were isolated from the femoral bone cavity and seeded in 96-well cell culture plates at a density of 6 × 10 4 cells/well. The BMSCs were cultured in Dulbecco's Modified Eagle Medium (DMEM, Gibco ® Cell Culture, Grand Island, NY, USA) supplemented with 10% fetal bovine serum (FBS), 1% penicillin/ streptomycin (Invitrogen, Carlsbad, CA, USA) and 10 mM L-glutamine (Gibco ® Cell Culture) at 37°C in a humid atmosphere G Wang, Z Zhu, C Lei et al.
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containing 5% carbon dioxide. The proliferation rate of the BMSCs was analysed every day for 7 days using the Alamar Blue™ assay (Biosource International, Camarillo, CA, USA) according to the manufacturer's instructions. Cell proliferation capacity was quantified spectrophotometrically by measuring absorbance at 570 and 600 nm using a Safire2™ microplate reader (Tecan Group, Männedorf, Switzerland).
OSTEOGENIC DIFFERENTIATION ASSAYS
The BMSCs from ovariectomized or control rats were seeded at a density of 2 × 10 5 cells/well in six-well culture plates and osteogenic differentiation assays were conducted. The BMSCs were maintained in 2 ml of an osteogenic induction medium containing DMEM plus 10 nM dexamethasone, 10 mM β-glycerophosphate and 0.2 mM ascorbic acid phosphate for 14 days or 21 days. The medium was changed twice weekly.
The osteogenic capacity of the cells was determined by Alizarin Red staining and alkaline phosphatase (ALP) staining. In addition, the enzymatic activity of ALP was measured. Staining for ALP was carried out using a commercial staining kit (Renbao, Shanghai, China) according to the manufacturer's instructions. Briefly, BMSCs were fixed on day 14 or 21, using buffered formalin for 30 s. After two washes with distilled water, the BMSCs were stained with the kit's staining reagent for 30 min and photographed using a light microscope fitted with an Olympus digital camera. Activity of ALP was determined by the conversion of a colourless substrate, p-nitrophenyl phosphate (pNPP; Sigma-Aldrich, St Louis, USA), to a coloured product, p-nitrophenol. Briefly, cells were rinsed twice with 1x phosphate-buffered saline (PBS), pH 7.4, followed by trypsinization and scraping the BMSCs into double-distilled water. This was followed by three cycles of freezing and thawing to disrupt the cell membrane. A 50-µl sample of the cell mixture was mixed with 50 µl pNPP (1 mg/ml) in 1 M diethanolamine buffer containing 0.5 mM magnesium chloride, pH 9.8, then incubated at 37°C for 15 min on a bench-top shaker. The reaction was stopped by the addition of 25 µl of 3 M sodium hydroxide per 100 µl of reaction mixture. Enzyme activity was quantified by measuring absorbance at 405 nm using a Safire2™ microplate reader. Total protein content was determined on aliquots of the samples by the bicinchoninic acid method using a commercial kit (Pierce Protein Research Products, Rockford, IL, USA). The ALP activity levels were normalized to the total protein content.
Extracellular matrix mineralization was determined by Alizarin Red-S staining for calcium deposition. Briefly, the cell cultures were washed twice with distilled water, fixed for 1 h in ice-cold 70% (v/v) ethanol, rinsed twice with deionized water and then stained for 10 min with Alizarin Red-S. After staining, excess dye was removed by washing the cells gently in running water. Calcification deposits, which appeared bright red under an optical microscope, were photographed. Osteogenic differentiation was ascertained by determining Alizarin Red-S staining density and area using the Multi Gauge V3.0 image analysis program (Fujifilm, Tokyo, Japan).
ADIPOGENIC DIFFERENTIATION ASSAYS
The BMSCs from ovariectomized or control rats were seeded at a density of 2 × 10 5 cells/well in six-well culture plates and adipogenic differentiation assays were G Wang, Z Zhu, C Lei et al.
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conducted. Cells were maintained in 2 ml of an adipogenic induction medium containing DMEM, supplemented with 100 nM dexamethasone and 1 µM insulin, for 14 days. Adipogenesis was then determined by Oil Red O staining. Cells were washed twice with 1x PBS and fixed with 10% formaldehyde for 30 min. After again washing twice in 1x PBS the cells were stained for 1 h in freshly diluted Oil Red O solution (six parts Oil Red O stock solution [0.5% Oil Red O in isopropanol] and four parts water). The stain was then removed and the cells were washed twice with 1x PBS. Images were obtained with an Olympus digital camera. Three images were taken and analysed for total droplet number using Image Pro Plus 5.0 software (Media Cybernetics, Silver Spring, MD, USA).
OSTEOCLASTOGENESIS ASSAY
The BMSCs, isolated from the femoral bone cavity of ovariectomized or control rats, were seeded in 96-well plates at a density of 1 × 10 4 cells/well and cultured in complete αmodified Eagle's Minimal Essential Medium (Gibco ® Cell Culture) supplemented with 10 ng/ml macrophage colony-stimulating factor (M-CSF), 10% FBS, 1% penicillin/streptomycin and 10 mM Lglutamine at 37°C in a humid atmosphere containing 5% carbon dioxide . The culture medium was changed every 2 days. To form multinucleated osteoclasts, from the time they were harvested, adherent cells were stimulated with 10 ng/ml M-CSF and 30 ng/ml recombinant receptor activator of nuclear factor κB ligand (R & D Systems, Minneapolis, MN, USA) for 5 -7 days until the formation of osteoclasts. Cells were fixed in 4% paraformaldehyde solution and osteoclastogenesis was evaluated by staining with tartrate-resistant acid phosphatase (TRAP) using a commercial kit (Sigma-Aldrich) according to the manufacturer's instruction. TRAP-positive osteoclasts were visualized under a light microscope and mature osteoclasts were classified as TRAPpositive cells that were stained pink and contained three or more nuclei.
DETECTION OF APOPTOTIC OSTEOCYTES
Proximal femoral bone was dissected from ovariectomized or control rats and fixed in 4% paraformaldehyde for 24 h. After fixation, tissues were dehydrated in alcohol, decalcified in 10% ethylenediaminetetraacetic acid at 4°C for 4 weeks, paraffinembedded and cut into consecutive 5 µmthick sections. To evaluate osteocytes undergoing apoptosis, sections were deparaffinized in xylene and rehydrated through a graded ethanol series, then analysed by terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate (dUTP) nick-end labelling (TUNEL) assay using the ApopTag ® Peroxidase In Situ Apoptosis Detection Kit (Millipore, Billerica, MA, USA), according to the manufacturer's instructions. Numbers of TUNEL-positive and TUNEL-negative osteocytes and empty lacuna were manually counted using light microscopy.
IMMUNOHISTOCHEMICAL ANALYSIS OF BCL-2 IN OSTEOCYTES
Immunohistochemistry was performed on 5 µm-thick paraffin-embedded proximal femoral bone sections from ovariectomized or control rats to detect B-cell lymphoma-2 (Bcl-2) protein in osteocytes. After deparaffinization in xylene and rehydration in graded concentrations of alcohol, antigen retrieval was achieved by treating sections with 0.01 M sodium citrate buffer solution (pH 6.0) at 90°C for 10 -15 min then with 3% hydrogen peroxide to block endogenous G Wang, Z Zhu, C Lei et al. Low-dose risedronate and bone protection peroxidase activity. The slides were then washed in 1 × Tris-buffered saline (TBS, pH 7.4). Nonspecific binding was blocked by incubating with 1.5% goat serum blocking solution (VectaStain ABC Kit; Vector Laboratories Inc., Burlingame, CA, USA) diluted in 1x PBS for 30 min. Sections were then incubated with an anti-Bcl-2 monoclonal antibody (C-2, Santa Cruz Biotechnology, 1 : 50 dilution in 1x PBS plus 0.3% Triton X-100 plus 0.1% bovine serum albumin; Santa Cruz, CA, USA) at 4°C in a humidified chamber overnight. A biotinylated goat antirat immunoglobulin G secondary antibody (1 : 200 dilution in 1x PBS containing 1.5% normal goat serum; VectaStain ABC kit) was then applied to the slides for 45 min at room temperature. After each antibody incubation step, the slides were washed several times in 1x PBS. Next, the slides were incubated with avidinconjugated peroxidase (VectaStain ABC kit) for 30 min and peroxidase activity was detected using a solution of 0.05% diaminobenzidine plus 0.01% hydrogen peroxide, which resulted in a brown precipitate at the antigen site. For negative controls, primary antibodies were replaced with normal mouse serum. Sections were counterstained with haematoxylin for 1 min and were mounted in DPX (Sigma-Aldrich). Immunostaining was quantified, using Bioquant Osteo II software (Bioquant Image Analysis Corp., Nashville, TN, USA), counting the number of osteocytes and empty lacunae in 20 different regions from the cortical bones of each rat femur and calculating the percentages of osteocytes and empty lacunae.
RT-PCR AND REAL-TIME PCR ANALYSES
The BMSCs were cultured until about 80 -90% confluent before total RNA was extracted. For tissues, total RNA was extracted using approximately 100 mg of proximal femoral bone tissues from ovariectomized or control rats. Total RNA was extracted using an RNeasy Mini Kit (Qiagen, Valencia, CA, USA) in accordance with the manufacturer's instructions.
Synthesis of cDNA was performed by reverse transcription (RT) using 2 µg of total RNA with 600 U of Moloney Murine Leukemia Virus reverse transcriptase, 60 U of RNase inhibitor, 15 mM of each deoxynucleotide triphosphate (all from Promega, Madison, WI, USA) and 300 µM of oligodeoxythymine (Genmed Scientifics, Wilmington, DE, USA) in a total volume of 20 µl. The samples were incubated at 42°C for 1 h and then heated for an additional 10 min at 92°C in a AVI 7300 thermal cycler (Eppendorf, Hamburg, Germany). Polymerase chain reaction (PCR) was performed using 1 µl of the cDNA first-strand product in a 20-µl reaction containing 2 × GoTaq ® Green Master Mix (Promega) and 0.5 µl each of the forward and reverse primers for Runx2 (core-binding factor subunit α-1 [Cbfa-1]), Bglap (osteocalcin), Pparg (peroxisome proliferator-activated receptor-γ-2 [PPAR 2]), Bcl2 (Bcl-2), Bax (Bcl-2-associated X protein [Bax]), Calcr (calcitonin receptor), Acp5 (TRAP) and Actb (β-actin) ( Table 1 ). The reaction mixture was heated to 95°C for 5 min followed by 30 cycles of amplification (94°C for 40 s, 60°C for 40 s and 72°C for 40 s) and a final extension at 72°C for 7 min. The PCR products were analysed by electrophoresis in 1.2% agarose gel and visualized using ethidium bromide staining and ultraviolet light.
For quantitative real-time RT-PCR analysis, the above PCR primers, reaction mix and conditions were performed in a 384well plate in an ABI Prism ® 7000 sequence 
STATISTICAL ANALYSES
All data were expressed as the mean ± SD. One-way analysis of variance was used to evaluate differences between variables across treatment groups. All statistical evaluations were performed using SPSS ® statistical software, version 13.0 (SPSS Inc., Chicago, IL, USA) for Windows ® . A P-value of < 0.05 was considered to be statistically significant.
Results
BMSC PROLIFERATION AND OSTEOGENIC DIFFERENTIATION
Compared with the ovariectomy control group, low-and high-dose risedronate sodium treatment significantly increased BMSC proliferation on days 6 and 7 of culture (P < 0.05; Fig. 1A ). BMSC proliferation was also significantly higher in the low-dose risedronate sodium group compared with the high-dose group on days 6 and 7 of culture (P < 0.05; Fig. 1A ).
Osteogenic differentiation in cultured BMSCs, as measured by ALP protein staining and enzyme activity, was significantly increased following risedronate sodium treatment in both the low-and high-dose treatment groups (2.2-and 1.9-fold, respectively, both P < 0.05) compared with the ovariectomy control group (Fig. 1B, 1C) . Extracellular matrix mineralization, as determined by Alizarin Red staining for calcium deposition, was also significantly increased in both the low-and high-dose risedronate sodium groups (P < 0.05 versus ovariectomy control; Fig. 1D, 1E ). In support of these findings, RT-PCR and real-time RT-PCR demonstrated that, in risedronate sodium-treated BMSCs, there was a significant increase in the osteogenic genes encoding for Cbfa-1 and osteocalcin ( Fig. 2A,  2B ) compared with the ovariectomy control group (P < 0.05). Increases were also greater in the low-dose risedronate sodium group compared with the high-dose group (P < 0.05).
ADIPOGENIC DIFFERENTIATION
Cultured BMSCs treated with risedronate sodium exhibited a significant decrease in Oil Red O-positive adipocyte clusters of approximately 50% compared with cells from ovariectomy control rats (P < 0.05;
TABLE 1: Summary of the forward and reverse primers used for the polymerase chain reaction procedure Gene (protein)
Forward primers Reverse primers
TGGTGGTGAAGACGCCAGTA CAAGTTCAACGGCACAGTCAA Cbfa-1, core-binding factor subunit α-1; PPARγ2, peroxisome proliferator-activated receptor-γ-2; Bcl-2, B-cell lymphoma-2; Bax, Bcl-2-associated X protein; TRAP, tartrate-resistant acid phosphatase. 
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OSTEOCYTE APOPTOSIS
Compared with the sham surgery group, abrupt oestrogen deficiency accelerated osteocyte apoptosis as demonstrated by a significant increase in the density of empty lacuna and number of apoptotic osteocytes (P < 0.05; Fig. 4A ). Treatment with risedronate sodium reversed this effect and significantly reduced the density of empty lacuna and the number of apoptotic osteocytes compared with ovariectomy control rats (P < 0.05; Fig. 4B, 4C) .
The number of Bcl-2-positive osteocytes was reduced after ovariectomy, as revealed by immunohistochemistry staining (Fig. 4D ). An increase in the percentage of Bcl-2positive osteocytes was observed in proximal 
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femur tissue from rats treated with risedronate sodium and this increase was significantly greater in the low-dose group compared with the high dose group (P < 0.05; Fig. 4D, 4E ). Bcl-2 was upregulated more than three-fold in the risedronate sodium-treated groups compared with controls as demonstrated by real-time RT-PCR ( Fig. 4F) . A decrease in the ratio of Bcl-2/Bax was observed in ovariectomized rats compared with the sham surgery group. Treatment with risedronate sodium restored the balance between Bcl-2 and Bax, as demonstrated by a significant increase in the Bcl-2/Bax ratio (Fig. 4G ).
OSTEOCLASTOGENESIS
As shown in Fig. 5A and 5B , formation of TRAP-positive, multinucleated osteoclasts was significantly increased after ovariectomy (P < 0.05). This increase was suppressed by treatment with risedronate sodium, which was associated with a decrease of approximately 20% in osteoclast numbers in both the low-dose and high-dose groups compared with the ovariectomy control group. Both TRAP and the calcitonin receptor mRNA levels were also significantly reduced following treatment with low-and high-dose risedronate sodium (P < 0.05; Fig.  5C, 5D ).
Discussion
Women are at high risk of perimenopausal bone loss 1,21 and current preventative therapies are limited. The effect of low-dose risedronate sodium in the prevention of rapid perimenopausal bone loss was investigated in the present study using a rat model of abrupt oestrogen deficiency in which the in vitro cellular profile of osteoblasts, adipocytes, osteocytes and osteoclasts was determined. Low-dose risedronate sodium effectively reversed the adverse effects of oestrogen deficiency on bone cells by enhancing osteoblast differentiation and reducing adipocyte differentiation, and by suppressing osteocyte apoptosis and osteoclast formation. In the low-dose treatment groups, risedronate 
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sodium was used at a dose of 0.24 µg/kg every 3 days, which is reflective of low-dose treatment in women where the most commonly reported dose employed is 5 mg/day 5 -10 or approximately 100 µg/kg per day.
Bone homeostasis requires a delicate balance between osteoblast and adipocyte differentiation. It has been shown that bone marrow mesenchymal stem cells isolated from postmenopausal patients with osteoporosis are more likely to undergo adipocyte differentiation than osteoblast differentiation. 22 Risedronate sodium enhanced osteogenic differentiation in the present study, as measured by an increase in ALP activity and an increase in extracellular matrix mineralization visualized by Alizarin Red staining. Furthermore, expression of genes encoding Cbfa-1 and osteocalcin, which are key regulators of osteoblast differentiation, 23 It is of note that the effects of risedronate sodium on osteogenic and adipogenic differentiation were significantly more pronounced in the low-dose compared with the high-dose treatment group. The findings from the present study are consistent with other reports demonstrating that bisphosphonates, oestrogens, statins and histone deacetylase inhibitors can stimulate osteogenic differentiation and suppress adipogenic differentiation. 18,24 -26 Apoptosis is an intrinsic process involving the activation of genes that can promote cell death. 27 Osteocyte viability plays an important role in bone integrity and, under certain conditions such as immobilization and oestrogen deficiency, compromised or dying osteocytes can trigger bone resorption. 28 -30 In agreement with published findings, the present study demonstrated 
that sudden oestrogen withdrawal resulted in a substantial increase in osteocyte apoptosis. 29 Low-dose risedronate sodium protected osteocytes from ovariectomyinduced apoptosis to a greater extent than treatment with higher doses. For a further assessment of possible mechanisms that protect against osteocyte apoptosis, the expression profiles of the Bcl2 (antiapoptosis) and Bax (proapoptosis) 31, 32 genes were investigated. Risedronate sodium enhanced expression of the Bcl2 gene and increased the Bcl2 / Bax expression ratio, indicating that risedronate-mediated protection against osteocyte apoptosis involves the regulation of Bcl2 and Bax expression.
A balance between bone formation by osteoblasts and bone resorption by osteoclasts is critical for bone homeostasis. Bone-resorbing osteoclasts have a key role in the development of osteoporosis. Accelerated osteoclast formation perturbs bone homeostasis and consequently results in bone loss. 33, 34 The present study showed that low-dose risedronate sodium suppressed osteoclast formation, as measured by a reduction in osteoclast number and expression of osteoclast genes encoding TRAP and the calcitonin receptor. These results are consistent with published studies that have demonstrated risedronate sodiummediated suppression of osteoclast differentiation via inhibition of the nuclear factor κB and nuclear factor of activated T cells, cytoplasmic 1 signalling pathways. 35 In addition, the present study was in agreement with a report that bone marrow cells from women treated with alendronate, another bisphosphonate, also exhibit reduced osteoclast formation. 36 These data suggest that risedronate sodium and other bisphosphonates have similar primary effects on the fate of osteoclasts after oestrogen deficiency.
In conclusion, the present study demonstrates that low-dose risedronate can reverse the primary effects of oestrogen deficiency on bone cells by enhancing osteoblast-mediated bone formation, suppressing osteoclast formation and adipocyte differentiation, and inhibiting osteocyte apoptosis. These data suggest that low-dose risedronate may have important bioactivity in protecting against perimenopausal bone loss. Low-dose risedronate sodium was more effective than high-dose treatment across several of the parameters measured but the mechanism for this difference remains to be fully determined.
